Cargando…

Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A population‐based study

Solitary plasmacytoma of bone (SPB) is a single, isolated plasmacytoma originated from the bone. The survival trends of patients with SPB in recent years remain unknown. And the prognostic system of SPB may also need to be refined. The 18 Surveillance, Epidemiology, and End Results (SEER) databases...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Xuxing, Liu, Shu, Wu, Chao, Wang, Jing, Li, Jianyong, Chen, Lijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877371/
https://www.ncbi.nlm.nih.gov/pubmed/33145987
http://dx.doi.org/10.1002/cam4.3533
_version_ 1783650153886908416
author Shen, Xuxing
Liu, Shu
Wu, Chao
Wang, Jing
Li, Jianyong
Chen, Lijuan
author_facet Shen, Xuxing
Liu, Shu
Wu, Chao
Wang, Jing
Li, Jianyong
Chen, Lijuan
author_sort Shen, Xuxing
collection PubMed
description Solitary plasmacytoma of bone (SPB) is a single, isolated plasmacytoma originated from the bone. The survival trends of patients with SPB in recent years remain unknown. And the prognostic system of SPB may also need to be refined. The 18 Surveillance, Epidemiology, and End Results (SEER) databases of the National Cancer Institute in the United States were used to extract data for this study. The third edition of the International Classification of Disease for Oncology (ICD‐O‐3) code 9731 was used to identify cases of SPB. For each case, factors including age at the time of diagnosis, sex, race, marital status, insurance status, primary sites of tumors, and the use of surgery were collected. The outcomes of patients with SPB were compared between two groups. And the prognostic impacts of baseline characteristics and use of surgery was studied. A total of 4103 (from 1976 to 2016) cases of SPB were identified. The median age was 65 years old. Patients in time period‐2 (2008–2016) show better survival as compared to those in time period‐1(1976–2007) (median overall survival: 88 months vs. 73 months, p = 0.0332). Age ≤ 65 years and being male were associated with better outcomes. The widowed individuals had significantly inferior survival and myeloma‐specific survival than the single, married, or divorced individuals (p values all <0.0001). Patients with lesions in bones of skull and face and associated joints had longer survival as compared with those with bone lesions in other sites (median overall survival: 107 months vs. 79 months, p = 0.0694). The use of surgery was significantly associated with improved survival (median survival: surgery performed 98 months vs. not performed 73 months, hazards ratio [HR]: 0.7623, 95% CI: 0.7009–0.8472; p < 0.0001) and myeloma‐specific survival (median myeloma‐specific survival: surgery 160.0 months vs. no surgery 143.0 months, HR: 0.8469, 95% CI: 0.7493–0.9572; p = 0.0078). Multivariable analysis revealed that surgery, marital status, and age were independent prognostic factors for overall survival in patients with SPB. The improvement in the survival of patients with SPB has been observed in recent years. And several potential prognostic factors were identified. Future prospective studies are warranted to explore the roles of novel agents, surgery, and systemic chemotherapy in the treatment of SPB.
format Online
Article
Text
id pubmed-7877371
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78773712021-02-18 Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A population‐based study Shen, Xuxing Liu, Shu Wu, Chao Wang, Jing Li, Jianyong Chen, Lijuan Cancer Med Clinical Cancer Research Solitary plasmacytoma of bone (SPB) is a single, isolated plasmacytoma originated from the bone. The survival trends of patients with SPB in recent years remain unknown. And the prognostic system of SPB may also need to be refined. The 18 Surveillance, Epidemiology, and End Results (SEER) databases of the National Cancer Institute in the United States were used to extract data for this study. The third edition of the International Classification of Disease for Oncology (ICD‐O‐3) code 9731 was used to identify cases of SPB. For each case, factors including age at the time of diagnosis, sex, race, marital status, insurance status, primary sites of tumors, and the use of surgery were collected. The outcomes of patients with SPB were compared between two groups. And the prognostic impacts of baseline characteristics and use of surgery was studied. A total of 4103 (from 1976 to 2016) cases of SPB were identified. The median age was 65 years old. Patients in time period‐2 (2008–2016) show better survival as compared to those in time period‐1(1976–2007) (median overall survival: 88 months vs. 73 months, p = 0.0332). Age ≤ 65 years and being male were associated with better outcomes. The widowed individuals had significantly inferior survival and myeloma‐specific survival than the single, married, or divorced individuals (p values all <0.0001). Patients with lesions in bones of skull and face and associated joints had longer survival as compared with those with bone lesions in other sites (median overall survival: 107 months vs. 79 months, p = 0.0694). The use of surgery was significantly associated with improved survival (median survival: surgery performed 98 months vs. not performed 73 months, hazards ratio [HR]: 0.7623, 95% CI: 0.7009–0.8472; p < 0.0001) and myeloma‐specific survival (median myeloma‐specific survival: surgery 160.0 months vs. no surgery 143.0 months, HR: 0.8469, 95% CI: 0.7493–0.9572; p = 0.0078). Multivariable analysis revealed that surgery, marital status, and age were independent prognostic factors for overall survival in patients with SPB. The improvement in the survival of patients with SPB has been observed in recent years. And several potential prognostic factors were identified. Future prospective studies are warranted to explore the roles of novel agents, surgery, and systemic chemotherapy in the treatment of SPB. John Wiley and Sons Inc. 2020-11-03 /pmc/articles/PMC7877371/ /pubmed/33145987 http://dx.doi.org/10.1002/cam4.3533 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Shen, Xuxing
Liu, Shu
Wu, Chao
Wang, Jing
Li, Jianyong
Chen, Lijuan
Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A population‐based study
title Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A population‐based study
title_full Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A population‐based study
title_fullStr Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A population‐based study
title_full_unstemmed Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A population‐based study
title_short Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A population‐based study
title_sort survival trends and prognostic factors in patients with solitary plasmacytoma of bone: a population‐based study
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877371/
https://www.ncbi.nlm.nih.gov/pubmed/33145987
http://dx.doi.org/10.1002/cam4.3533
work_keys_str_mv AT shenxuxing survivaltrendsandprognosticfactorsinpatientswithsolitaryplasmacytomaofboneapopulationbasedstudy
AT liushu survivaltrendsandprognosticfactorsinpatientswithsolitaryplasmacytomaofboneapopulationbasedstudy
AT wuchao survivaltrendsandprognosticfactorsinpatientswithsolitaryplasmacytomaofboneapopulationbasedstudy
AT wangjing survivaltrendsandprognosticfactorsinpatientswithsolitaryplasmacytomaofboneapopulationbasedstudy
AT lijianyong survivaltrendsandprognosticfactorsinpatientswithsolitaryplasmacytomaofboneapopulationbasedstudy
AT chenlijuan survivaltrendsandprognosticfactorsinpatientswithsolitaryplasmacytomaofboneapopulationbasedstudy